We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Ocuphire Pharma, announced today the closing of its previously announced registered direct offering of 3,076,923 shares of the Company's common stock (the "Shares") and warrants to purchase 1,538,461 shares of the Company's common stock (the "Warrants"
Ocuphire Pharma has successfully enrolled 39 glaucoma patients in ORION-1 at 5 U.S. sites from late May to August 2019. The objectives of the randomized...